This is a working overview of Reversed-phase HPLC, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-09-02 and is reviewed periodically as new material appears.
Tirzepatide is a synthetic peptide that activates both the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. This dual agonist profile distinguishes it from earlier incretin-based compounds that act on a single receptor. The molecule was engineered from the native GIP sequence and carries several non-natural residues that slow enzymatic breakdown. Researchers designed it to combine the insulinotropic effects of GIP signaling with the appetite and gastric-emptying effects associated with GLP-1 activation.
Development of tirzepatide took place under a research program that sought to test whether simultaneous engagement of two incretin receptors would produce greater metabolic effects than single-receptor agonism. Clinical trials were organized into the SURPASS series for type 2 diabetes and the SURMOUNT series for obesity and weight management. Regulatory clearance for type 2 diabetes came in 2022 in the United States, followed by approval for chronic weight management in 2023. The trial programs reported reductions in glycated hemoglobin and body weight relative to comparators, though long-term cardiovascular and durability data continue to accumulate.
Dual agonism at the GIP and GLP-1 receptors underlies the observed pharmacology. Activation of GLP-1 receptors raises glucose-dependent insulin release, lowers glucagon secretion, slows gastric emptying and reduces appetite. GIP receptor activation contributes additional effects on adipose tissue and on energy balance, and the combined action on appetite appears larger than either pathway alone in animal models. Signalling bias and the relative contribution of each receptor arm to weight-related effects remain areas of active investigation.
Structure-activity work shows that fatty acid length, linker chemistry and the position of acylation all influence albumin affinity and receptor potency. Plasma protein binding exceeds 99 percent, which restricts distribution and slows renal clearance. Degradation proceeds largely through general proteolysis and fatty acid oxidation rather than cytochrome P450 metabolism, so exposure to common oxidative drug interactions is limited. Whether these clearance routes vary meaningfully between individuals is not fully established.
The molecule is a synthetic 39-amino-acid peptide whose backbone derives from the sequence of human glucose-dependent insulinotropic polypeptide, with several substitutions that raise metabolic stability and shift receptor preference. A C20 fatty diacid is attached through a short linker to a lysine side chain, a modification that increases binding to serum albumin. The reported monoisotopic mass is approximately 4813 Da. Near neutral pH the peptide carries a net negative charge, and the lipid tail makes the molecule markedly more hydrophobic than the unmodified parent sequence.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Modified synthetic peptide | 39-residue backbone with non-natural residues |
| Receptor targets | GIP and GLP-1 | Dual incretin receptor agonist |
| Approximate molecular mass | 4,813 Da | Calculated from the peptide sequence |
| Administration route | Subcutaneous injection | Weekly schedule in approved products |
| Albumin binding | Present | Mediated by a C20 fatty diacid side chain |
Research-grade material circulates through suppliers that differ widely in documentation and testing practice, so a certificate of analysis is a starting point rather than proof of quality. Independent verification typically repeats chromatographic purity and mass confirmation on the received lot, and compares results against a retained reference standard. Regulatory status varies by jurisdiction, and a substance cleared as a medicine is not interchangeable with a research chemical of the same name. Open questions include how closely non-pharmaceutical lots match approved material in impurity profile and in aggregate content.
Solid tirzepatide is handled as a lyophilised, hygroscopic peptide powder that should be kept desiccated, protected from light, and stored frozen, typically at or below minus twenty degrees Celsius for long-term retention. Material left at ambient temperature for extended periods can take up moisture, which promotes aggregation and deamidation. Commercial liquid presentations are kept refrigerated between two and eight degrees Celsius and are not frozen. Reconstituted laboratory solutions are generally held cold and used within a short window because hydrolysis and oxidation continue slowly in solution.
Identity and purity are usually established with reversed-phase high-performance liquid chromatography for the main peak and with mass spectrometry for the observed molecular mass. Peptide mapping after enzymatic digestion confirms the primary sequence, while amino acid analysis provides a quantitative composition check. Size-exclusion chromatography and ion-exchange chromatography are used to look for aggregates and charge variants. Water content, residual solvents, and counter-ion content are measured separately, since a lyophilised powder is often reported on an as-is basis unless a correction is applied.
The GIP receptor is expressed in pancreatic islets, adipose tissue, and the central nervous system, while GLP-1 receptors are found in pancreatic islets, the gastrointestinal tract, and the brain. Activation of both receptors can enhance glucose-dependent insulin secretion and reduce glucagon release. The relative contribution of each receptor to the overall pharmacological effect remains an area of ongoing investigation. Preclinical studies suggest that GIP receptor agonism may modulate appetite and energy balance, but the precise mechanisms in humans are not fully established.
In clinical research, tirzepatide has been studied in randomized controlled trials for glycemic control and body weight reduction. These trials typically measure changes in hemoglobin A1c and body weight over periods of several months. The drug is administered by subcutaneous injection, and its pharmacokinetic profile supports once-weekly dosing. Post-marketing surveillance continues to evaluate long-term outcomes and rare adverse events.
Identity and purity are assessed by reversed-phase high-performance liquid chromatography, with mass confirmation by electrospray ionisation mass spectrometry. Peptide mapping after enzymatic digestion verifies the primary sequence. Size-exclusion chromatography quantifies aggregates, while circular dichroism provides a secondary-structure fingerprint. Bioanalytical quantification in plasma uses immunoassay or LC-MS/MS. Reported purity for research-grade lots is commonly 95 percent or higher, and residual water content is checked by Karl Fischer titration.
As a peptide, tirzepatide is handled as a lyophilised solid in research settings and as a preserved solution in finished products. Aqueous solubility is pH dependent and reaches a minimum near the isoelectric point, which lies close to pH 5.4. Stock solutions are typically prepared in neutral or slightly basic buffer to limit precipitation. The solid is hygroscopic and should be equilibrated to room temperature before opening so that condensation does not form on the powder surface.
The compound first appeared in the scientific literature as an investigational agent for type 2 diabetes. Clinical development proceeded through phase 1, phase 2, and phase 3 programs that measured glycemic control as a primary endpoint while recording body weight as a secondary outcome. Regulatory approval in the United States followed in 2022 for glycemic control, and a separate indication for chronic weight management was added later. Subsequent trials have examined cardiovascular outcomes in adults with elevated cardiovascular risk. Debates continue over how much of the observed effect derives from each receptor arm.
Structural work on the molecule centers on a C20 fatty diacid moiety attached through a linker to the peptide backbone. This side chain promotes reversible binding to serum albumin, which slows renal clearance and supports a prolonged action profile. The peptide backbone incorporates aminoisobutyric acid substitutions that limit recognition by digestive enzymes. Together these modifications produce a molecule that is stable enough for subcutaneous delivery but still dependent on careful manufacturing control. Analytical characterization of the active pharmaceutical ingredient typically follows the conventions used for other synthetic peptides.
Ethyleneoxynitazene (tetrahydrofuranitazene) is a benzimidazole derivative which has been sold as a designer drug over the internet and has opioid effects, though with lower potency than etonitazene itself It is an analogue of etonitazene where the 4-ethoxy group attached to the benzyl ring has been cyclised round to the 3-position to form a 2,3-dihydrobenzofuran ring system. It was first reported in Estonia in February 2023, subsequently in the UK in late 2023 and in China July 1st.
The coexistence of PPII and beta-turn play an important role of increasing entropy as resilin returns to its disordered form. The other function of PPII is to facilitate self-assembling process: it is found that the quasi-extended PPII is able to interact through an intermolecular reaction, and initiate the formation of fibrillar supramolecular structure.
Due largely to the US EPA's Acid Rain Program, the U.S. has had a 33% decrease in emissions between 1983 and 2002 (see table). This improvement resulted in part from flue-gas desulfurization, a technology that enables SO2 to be chemically bound in power plants burning sulfur-containing coal or petroleum.
=== Wallets === A number of technologies known as wallets exist that store the key value pair of private and public key known as wallets. A wallet hosts the details of the key pair making cryptocurrency transactions possible. Multiple methods exist for storing keys or seeds in a wallet. A brainwallet or brain wallet is a type of wallet in which one memorizes a passcode (a private key or seed phrase). Brainwallets may be attractive due to plausible deniability or protection against governmental seizure, but are vulnerable to password guessing (especially large-scale offline guessing). Several hundred brainwallets exist on the Bitcoin blockchain, but most of them have been drained, sometimes repeatedly.
Sources: en.wikipedia.org
=== Kalaghatgi === Following the 2008 delimitation of Karnataka's constituencies, Lad contested the Kalaghatgi Assembly constituency on a Congress ticket. He defeated BJP candidate C. M. Nimbannavar by 11,642 votes, receiving 49,733 votes. In the 2013 Karnataka Legislative Assembly election, Lad was re-elected from Kalaghatgi. He received 76,802 votes, defeating his nearest rival by more than 45,000 votes. In 2018, Lad contested Kalaghatgi again but was defeated by BJP candidate C. M. Nimbannavar. Nimbannavar received 83,267 votes compared with Lad's 57,270, a margin of 25,997 votes. Lad returned to the Assembly in the 2023 Karnataka election. He won Kalaghatgi with 85,761 votes, defeating BJP candidate Nagaraj Chebbi, who received 71,404 votes. The margin was 14,357 votes.
The first two bus operating contracts for the new Weaver Network were awarded in September 2026 to FirstGroup, covering Huddersfield and parts of Leeds, and Transdev Blazefield, covering Dewsbury. In October 2021, £830 million of funding was announced for the West Yorkshire Combined Authority through the City Region Sustainable Transport Settlement, including funding to develop mass transit proposals for the region. Consultation was undertaken between July and September 2024 on proposed tram routes linking Bradford and Leeds, and St. James Hospital, central Leeds and White Rose Shopping Centre. Following a review by the National Infrastructure and Service Transformation Authority, the programme was moved to a more sequential approach intended to reduce delivery risk, contributing to a delay in the expected timetable for the scheme.
Preventing DAMP release – proapoptotic therapies, platinums, ethyl pyruvate Neutralizing or blocking DAMPs extracellularly – anti-HMGB1, rasburicase, sRAGE, etc. Blocking the DAMP receptors or their signaling – RAGE small molecule antagonists, TLR4 antagonists, antibodies to DAMP-R DAMPs can be used as biomarkers for inflammatory diseases and potential therapeutic targets. For example, increased S100A8/A9 is associated with osteophyte progression in early human osteoarthritis, suggesting that S100 proteins can be used as biomarkers for the diagnosis of the progressive grade of osteoarthritis. Furthermore, DAMP can be a useful prognostic factor for cancer. This would improve patient classification, and a suitable therapy would be given to patients by diagnosing with DAMPs. The regulation of DAMP signaling can be a potential therapeutic target to reduce inflammation and treat diseases. For example, administration of neutralizing HMGB1 antibodies or truncated HMGB1-derived A-box protein ameliorated arthritis in collagen-induced arthritis rodent models. Clinical trials with HSP inhibitors have also been reported. For nonsmall-cell lung cancer, HSP27, HSP70, and HSP90 inhibitors are under investigation in clinical trials. In addition, treatment with dnaJP1, which is a synthetic peptide derived from DnaJ (HSP40), had a curative effect in rheumatoid arthritis patients without critical side effects. Taken together, DAMPs can be useful therapeutic targets for various human diseases, including cancer and autoimmune diseases.
Coca leaves have been used by indigenous South Americans for thousands of years, both as a stimulant and for medicinal purposes. When the Spanish arrived in South America, they initially banned coca but soon legalized and taxed it after seeing its importance to local labor. The active ingredient was first isolated in 1855 by Friedrich Gaedcke and later refined by Albert Niemann, who named it "cocaine". In the late 1800s, cocaine became popular in Western medicine as a local anesthetic and was widely used in various products, including drinks and remedies. and James Leonard Corning demonstrated peridural anesthesia. However, due to its toxic effects and potential for abuse, safer alternatives eventually replaced it in medical practice. Large-scale coca cultivation and cocaine production occurred in Asia, on Taiwan (then known as Formosa) and Java (today part of Indonesia) before World War II. Since the 1980s, the cocaine trade was dominated by centralized, hierarchical drug cartels such as Medellín and Cali, along with their successors and early FARC factions. By the early 2000s, this model fragmented into a diverse network of global trafficking links, allowing South American cocaine production to easily supply markets in Europe, Africa, Asia, and Oceania through various routes.
When the backbone bonds cleave, six different types of sequence ions are formed as shown in Fig. 1. The N-terminal charged fragment ions are classed as a, b or c, while the C-terminal charged ones are classed as x, y or z. The subscript n is the number of amino acid residues. The nomenclature was first proposed by Roepstorff and Fohlman, then Biemann modified it and this became the most widely accepted version. Among these sequence ions, a, b and y-ions are the most common ion types, especially in the low-energy collision-induced dissociation (CID) mass spectrometers, since the peptide amide bond (CO-NH) is the most vulnerable and the loss of CO from b-ions. Mass of b-ions = Σ (residue masses) + 1 (H+) Mass of y-ions = Σ (residue masses) + 19 (H2O+H+) Mass of a-ions = mass of b-ions – 28 (CO) Double backbone cleavage produces internal ions, acylium-type like H2N-CHR2-CO-NH-CHR3-CO+ or immonium-type like H2N-CHR2-CO-NH+=CHR3. These ions are usually disturbance in the spectra.
Sources: en.wikipedia.org
It binds and activates both the GIP and GLP-1 receptors, making it a dual incretin receptor agonist. Single-receptor GLP-1 agonists act on one target only. The dual profile is the defining pharmacological feature of the molecule.
A fatty diacid side chain promotes reversible binding to serum albumin. This association slows renal clearance and protects the peptide from rapid enzymatic degradation. The result is a prolonged circulation time that supports weekly administration.
The first regulatory approval, for type 2 diabetes, was granted in the United States in 2022. An additional approval for chronic weight management followed in 2023. Availability and approved indications vary by country and are set by each national regulator.
It is a synthetic peptide of 39 amino acids bearing a lipid side chain. Its size and architecture place it outside the small-molecule class, and laboratories generally handle it with the precautions used for biologic-like molecules.